Kaye Introduces the Kaye® Log -80 Vaccine Temperature Logger for Cold Chain Market to Address COVID-19 Vaccine Storage and Transportation Requirements
Kaye has been a leader for over 60 years in the Validation and Monitoring of critical process data. With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain. This NFC Logger with external probe allows the precise recording and monitoring of products that are using Dry Ice pellets for Cold Chain shipment and storage. Shipments of vaccines and plasma at -70°C (-94°F) are very sensitive for breaking of the container seal, which will quickly allow the internal temperatures to rise to a critical level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005380/en/
Kaye Log -80 Vaccine Temperature Logger (Photo: KAYE)
Drugs, vaccines, blood and biological materials are extremely sensitive to temperature variations. They must be kept and transported within a controlled temperature range during storage and transit; these are well known facts. However, during the recent fight against the COVID-19 Pandemic and with vaccines on the horizon, the demand for 24/7 temperature monitoring within the Cold Chain received another requirement, ultra-low measurements down to -70C. Besides the technology of monitoring at ultra-cold temperatures, the requirement of fast access to the temperature data without disturbing the integrity of the packaging, is foremost. Any removal of the logging device from the package, use of USB and local software applications will impede the process flow. Threshold LEDS allow the recipient to quickly see if the threshold limits have been breached, and with a quick swipe of an NFC device, all data is loaded to a local smart phone application and to the KayeTrack cloud, with corresponding email alerts, emailed PDF reports and GPS location information.
The Kaye Log -80 Vaccine Temperature Logger is an extension of Kaye’s Cold Chain solutions. From Thermal Validation, Continuous Monitoring, and Cold Chain Loggers, Kaye is committed to providing accurate, reliable, secure data and systems to help ensure the quality of all Pharma/Biotech products.
For information on the product, please visit https://www.kayeinstruments.com/kaye-log-80-vaccine-temperature-logger
About Kaye
For more than sixty years, Kaye has been at the forefront of high accuracy process measurement, for applications from thermal process validation and environmental and cold chain monitoring, to sensor calibration. https://www.kayeinstruments.com
Kaye is a subsidiary of Amphenol Corporation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005380/en/
Contact information
Nicole Rauenbühler; Global Marketing Manager
E-Mail: news@amphenol-sensors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nakiki SE: Nakiki SE Evaluates Corporate Bond Offering for Strategic Bitcoin Investment27.8.2025 19:51:00 EEST | Press release
Nakiki SE is currently evaluating the issuance of a corporate bond with a target volume in the mid–single-digit million-euro range. As part of a pre-market sounding process, the Management Board is assessing interest from professional investors. The proceeds of the issuance are intended primarily for the acquisition of Bitcoin. Language: English Company: Nakiki SE Hanauer Landstr. 204 60314 Frankfurt on the Main Germany E-mail: info@nakikifinance.com Internet: https://nakikifinance.com/ ISIN: DE000WNDL300, DE000WNDL318 WKN: WNDL30, WNDL31 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange View source version on businesswire.com: https://www.businesswire.com/news/home/20250827593566/en/
Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm27.8.2025 18:30:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced it has been named a Leader in The Forrester Wave™: Integration Platform As A Service, Q3 2025. The report evaluated the 10 most significant iPaaS vendors, and Boomi achieved the highest score in thestrategy category among all evaluated providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826324359/en/ Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm The report states that Boomi has reoriented with an “intense focus on AI and APIs,” “receives strong feedback from its partners,” and maintains “clear investment priorities.” Reference customers were impressed by the company’s level of investment in the product and its vision for the future, and look forward to seeing Boomi deliver on its AI roadmap. “We’re honored to be named a Leader in the Forrester Wave — and especially proud to receive the to
Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences27.8.2025 17:00:00 EEST | Press release
Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulatory writing by reducing variability and improving the quality, consistency, and speed of documentation. Evidence Matters’ RegulatoryFlow platform (“RegFlow”) and specialized services unify clinical data and documents, simplify workflows, and accelerate the work of key life sciences professionals, from medical writers to regulatory specialists. “We are excited to work alongside Evidence Matters to co-develop technology that directly enhances the quality and efficiency of regulatory writing,” said Nicole Maciolek, Vice President,
Andersen Consulting Adds Collaborating Firm Skribble27.8.2025 16:30:00 EEST | Press release
Andersen Consulting expands its strategy and business transformation capabilities through a Collaboration Agreement with Skribble, a digital and brand consultancy supporting innovation and operational transformation for companies in Southeast Asia. Established in 2020, Skribble offers a wide range of services, including brand and communications strategy, digital marketing, custom technology development, change management, and platform solutions. The firm supports organizations in real estate, consumer goods, banking, and government by aligning strategy with execution to deliver integrated brand, performance, and technology solutions. With a focus on process optimization and a full creative and technical skillset, Skribble helps clients drive transformation and growth. “At Skribble, we pride ourselves on translating creative energy into strategic outcomes,” said Chan Leong, CEO of Skribble. “We approach each client with precision and passion, applying deep market insight, sharp executio
Veridas Named a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification27.8.2025 15:34:00 EEST | Press release
Veridas, a global identity company, has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification, reinforcing its position among the top global IDV vendors. Founded in 2017 and operating globally, Veridas enters the report as one of the fastest-growing companies in the market. Gartner defines Visionaries as vendors that understand where the market is going or have a vision for changing market rules. This positioning validates Veridas’ long-term strategy and highlights its leadership in innovation, ethical design, and user-centric digital identity. At the core of Veridas’ approach is its 100% proprietary technology stack, covering facial biometrics, voice authentication, document verification, age validation, physical access control, and its ID Wallet. By developing all core technologies in-house, Veridas ensures full control over security, performance, and compliance, enabling end-to-end protection against fraud, higher user conversion rates, and gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom